Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pulmonary Arterial Hypertension Market 

5.1. COVID-19 Landscape: Pulmonary Arterial Hypertension Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pulmonary Arterial Hypertension Market, By Drug Class

8.1. Pulmonary Arterial Hypertension Market, by Drug Class, 2023-2032

8.1.1 Endothelin Receptor Antagonists (ERAs)

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. PDE-5 Inhibitors

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Prostacyclin and Prostacyclin Analogs

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. SGC Stimulators

8.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Pulmonary Arterial Hypertension Market, By Type

9.1. Pulmonary Arterial Hypertension Market, by Type, 2023-2032

9.1.1. Branded

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Generics

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Pulmonary Arterial Hypertension Market, By Route of Administration 

10.1. Pulmonary Arterial Hypertension Market, by Route of Administration, 2023-2032

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Intravenous/ subcutaneous

10.1.2.1. Market Revenue and Forecast (2020-2032)

10.1.3. Inhalational

10.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Pulmonary Arterial Hypertension Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.2. Market Revenue and Forecast, by Type (2020-2032)

11.1.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Type (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Type (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Type (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Type (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Type (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Route of Administration (2020-2032)

Chapter 12. Company Profiles

12.1. Actelion Pharmaceuticals (now part of Janssen Pharmaceuticals)

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Gilead Sciences

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. United Therapeutics Corporation

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GlaxoSmithKline

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Pfizer

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Arena Pharmaceuticals

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Reata Pharmaceuticals

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Lung Biotechnology

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Acceleron Pharma

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms